Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Greenlighting Dozens Of New Trials For Coronavirus Therapeutics

Executive Summary

In less than three weeks, the number of clinical trials for potential treatments has jumped to 72, according to the FDA’s Coronavirus Treatment Acceleration Program.

You may also be interested in...



US FDA Not Missing Assessment Goals, But Guidance Reminds That It’s Possible

New Q&A guidance also states that its near-term focus for resources will be on coronavirus and some other conditions.

US FDA Pushing Coronavirus Trial Sponsors To Include Control Groups

“We still try hard to get people to have a control group,” Bob Temple says in an interview. “Not everybody always wants to have a control group. We've been trying hard to do it.”

When A Sponsor Wants To Proceed On A COVID Product, US FDA Almost Never Says No

Bob Temple tells the Pink Sheet that many of the drugs that sponsors are bringing forward have “not much evidence” of antiviral properties, “but it's still worth trying.” Jacqueline Corrigan-Curay emphasizes that even as FDA responds to the enormous coronavirus challenge, the agency's other work continues.

Related Content

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel